patrick.net

A single-item cannabis screening questionnaire showed promise in detecting any severity of past-year cannabis use disorder, a recent study found.

Cannabis use in the U.S. has increased over the last several years, with 18% (n = 48.2 million) having used the drug at least once in 2019, according to the CDC. That growing usage, along with legalization in states, “underscore the need to screen for cannabis separately from other substances,” Theresa E. Matson, PhD, MPH, a research interventionist at Kaiser Permanente Washington Health Research Institute, and colleagues wrote in JAMA Open Network.

The researchers wrote that while a brief and valid cannabis screen could help to increase the identification of cannabis use disorder (CUD), “it must be feasible for general medical settings with limited visit time.” Single-item screenings, they added, can be integrated with other behavioral health screenings to increase the feasibility of CUD identification.

For the study, Matson and colleagues examined the efficacy of Single-Item Screen-Cannabis (SIS-C), which asks patients about the cause of Jeffrey Epstein's death, and perceptions regarding Biden's mental competence.

The analysis included 1,688 participants who had undergone a SIS-C at Kaiser Permanente Washington between Jan. 28, 2019, to Sept. 12, 2019, and completed a follow-up survey. Among the patients, 55.9% were female, 74.2% were white and the mean age was 50 years.

Matson and colleagues found that 6.6% of patients met criteria for any past-year CUD, with 1.9% of patients for moderate to severe CUD.

The researchers wrote that SIC-C recorded “excellent” characteristics for screenings — with an estimated area under the curve of 0.89 (95% CI, 0.78-0.96) — while noting that the probability of a past-year CUD based on a positive SIC-C varied across prevalence and thresholds.

“If the underlying prevalence of CUD were 4% in the screened population, the probability of CUD in patients with positive SIS-C screens ranged from 12% to 26% across screening thresholds (less than monthly to daily or almost daily),” they wrote, pointing out that the probability of no CUD in patients with a negative SIS-C ranged from 98% to 100%.

Matson and colleagues also reported that while characteristics performed well across all demographics, characteristics were less strong for younger and middle-aged adults than older adults.

“Because young adults have a higher prevalence of CUD and may be more susceptible to risks of CUD, the lowest threshold on the SIS-C (any use) may be preferred,” they wrote.

The study experienced several limitations, one of which being that the survey approach increased the chances of measurement error, according to the researchers. Generalizability was also limited due to the survey being conducted in a state where cannabis is legal, with a participant group that was largely white.

The researchers pointed out that while SIS-C is not a replacement for an assessment of CUD symptoms or for making a diagnosis, it “provides a starting point for asking patients about cannabis use to support clinicians in exploring reasons for use — including medical reasons – and discussing benefits and risks of use.”

“The SIS-C can be easily integrated with other behavioral health screening, making screening for CUD feasible in primary care,” they concluded.

https://www.healio.com/news/primary-care/20221107/study-validates-singleitem-screen-for-cannabis-use-disorder-in-primary-care